Market Overview

Receptos Up 8%; Wedbush Sees Possible Takeover

Related RCPT
Celgene's Q2 Earnings Call: Highlights & Analyst Commentary
Evercore ISI's Schoenebaum Breaks Down Celgene-Receptos Merger
NantKwest Surges As Biggest Biotech Market Cap IPO (Investor's Business Daily)

Receptos (NASDAQ: RCPT) closed Monday just short of a 52-seek high after an analyst suggested the drug development company could become a takeover candidate.

Receptos is developing drugs for a range of immune system disorders including its lead product for multiple sclerosis and inflammatory bowel disease.

Wedbush's Liana Mousatos, who reiterated an Outperform rating and $63 target, said a conference slated for September 10 in Boston could become a venue for the company to unveil positive data from current drug trials.

Mousatos expects a Phase II trial of its treatment for inflammation of the esophagus to launch in the second half of 2014 along with release of interim results from a trial of its colitis drug.

Receptos closed Monday at $50.69, up 8.24 percent.

Latest Ratings for RCPT

Jul 2015Evercore PartnersDowngradesBuyHold
Jul 2015NomuraDowngradesBuyNeutral
Jul 2015BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for RCPT
View the Latest Analyst Ratings

Posted-In: Liana MousatosAnalyst Color News Price Target Reiteration FDA After-Hours Center Analyst Ratings


Related Articles (RCPT)

Get Benzinga's Newsletters